Getty Images +4% – What’s Going On?
Getty Images shares surge as it partners with FILMPAC, offering premium stock footage and production services to meet growing demand for authentic content.
Semler Scientific +28% After Adopting Bitcoin As Primary Treasury Reserve Asset: What’s Going On?
Semler Scientific's shares surge after adopting Bitcoin as its primary treasury reserve asset, purchasing 581 bitcoins for $40 million.
Asahi Kasei Makes $1.1B Offer For Swedish Drugmaker Calliditas Therapeutics, Enhancing Pharma Growth Strategy
Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi Kasei's global presence in immunology and renal disease markets, aligning with its strategic growth and expansion in the U.S. and Europe.
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates and fees.
What’s Going On With Mullen Automotive Stock Tuesday?
Mullen Automotive unveils a zero-emission version of their PowerUP mobile charging truck, meeting market demand for sustainability.
Why Sharps Technology Shares Are Skyrocketing Today
Sharps Technology shares surge as it entered into a series of agreements with Nephron SC and Nephron Sterile Compounding Centers.
What’s Going On With Texas Instruments Stock After Activist Elliott Bags $2.5B Stake?
Elliott's $2.5 billion stake in Texas Instruments prompts calls for enhanced free cash flow through a dynamic Capex strategy. TXN shares edge higher.
To Leave Or Not To Leave Russia? Western Firms Grapple With Dilemma Amid Rising Costs And Bureaucratic Hurdles
As the corporate exodus from Russia faces increasing complications, multinational companies are finding themselves caught between a rock…
Aerospace Giant TransDigm Expands Empire, Acquires Raptor Scientific For $655M
TransDigm Group is set to acquire Raptor Scientific for $655 million in cash. Raptor Scientific, owned by L Squared Capital Partners, specializes in complex test and measurement solutions for aerospace and defense, generating nearly all revenue from proprietary products.
Merck’s Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study
Merck's KEYNOTE-522 trial shows Keytruda combined with chemotherapy significantly improves overall survival in high-risk early-stage triple-negative breast cancer patients compared to chemotherapy alone.